Overview of Primary Provisions of U.S. and French Sunshine Reporting Requirements

more+
less-

2013 was a year of unprecedented scrutiny of financial relationships between manufacturers and health care professionals, such as physicians. Both the United States and France imposed sweeping new reporting and disclosure requirements in an effort to provide transparency and, theoretically, to enable the public – including patients – to make informed treatment decisions and assess possible conflicts of interest. Both sets of requirements carry potentially large financial penalties for failure to report and for incorrect reporting. For manufacturers operating globally, compliance with these provisions will be an ongoing challenge.

At the same time, a review of the highlights of the two Sunshine Acts demonstrates that transparency is not necessarily the same on one side of the Atlantic as the other.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Conflicts of Interest, Disclosure Requirements, Healthcare, Manufacturers, Penalties, Pharmaceutical Manufacturers, Sunshine Act, Transparency

Published In: General Business Updates, Health Updates, International Trade Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Reed Smith | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »